Skinvisible Web Sign Up for Updates         T 702.433.7154
Skinvisible - Polymer Delivery System

The Ultimate Polymer Delivery System.

SEC Filings

No longer required...

Stock Information:

  SKVI quote
  Press Releases

Sign up for Skinvisible Inc. Updates:
Click here to join our mailing list.

May 21, 2024
Skinvisible files patent application for the transdermal treatment of obesity: "Transdermal Delivery Composition for Delivery CB-1 Receptor Antagonists and/or GPL-1 Receptor Agonist, and Method of Delivery."

February 14, 2024
Skinvisible Announces Significant Progress In Licensee's Clinical Trials For Invisicare Formulation Targeting Nethertons Syndrome

June 6, 2022
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug Application

More News...

Home    |     About us    |    Technology    |    Products    |    Investors    |    Contact Us    |    Disclaimer & Privacy    |     Sign Up for Updates
© 2008 Skinvisible Pharmaceuticals, Inc.     Note: This website is not intended for Canadian residents.